Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialResearch in context

Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trialResearch in context

Summary: Background: SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity. This study aimed to evaluate the efficacy and safety of SIM0417 plus ritonavir (a pharmacokinetic enhancer) in adults with COVID-19. Methods: This...

Full description

Bibliographic Details
Main Authors:	Fuxiang Wang, Wen Xiao, Yimin Tang, Mengli Cao, Dan Shu, Tetsuya Asakawa, Yechun Xu, Xiangrui Jiang, Leike Zhang, Wei Wang, Jianxing Tang, Yuansheng Huang, Yang Yang, Yumei Yang, Renhong Tang, Jingshan Shen, Hongzhou Lu
Format:	Article
Language:	English
Published:	Elsevier 2023-09-01
Series:	The Lancet Regional Health. Western Pacific
Subjects:	Covid-19 3CL protease inhibitor SARS-CoV-2 viral load Alleviation of COVID-19 symptoms
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666606523001530

Similar Items

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

The effect of lopinavir - ritonavir on mortality in COVID-19 pneumonia
by: Muhammed Emin Demirkol, et al.
Published: (2024-10-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trialResearch in context
by: Yangqing Zhan, et al.
Published: (2024-01-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
by: José Wagner Leonel Tavares-Júnior, et al.
Published: (2023-06-01)

Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
by: Zhang Y, et al.
Published: (2024-04-01)

Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort
by: Dóra Paróczai, et al.
Published: (2025-01-01)

Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
by: Fatemeh Saheb Sharif-Askari, et al.
Published: (2024-10-01)

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
by: Xiang Z, et al.
Published: (2024-01-01)

Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trialResearch in context
by: Bei Wang, et al.
Published: (2023-09-01)

The Efficacy and Safety of Adding Chlorpromazine to Atazanavir/Ritonavir Regimen in the Treatment of Moderate COVID-19 Patients, a Randomized Double-blind Clinical Trial
by: Sima Ramezaninejad, et al.
Published: (2023-07-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
by: Ivan Gentile, et al.
Published: (2023-12-01)

A Real-World Retrospective Study on the Efficacy and Safety of Four Antiviral Drugs for Hospitalized COVID-19 Patients: Nirmatrelvir/Ritonavir, Simnotrelvir/Ritonavir, Molnupiravir and Azvudine
by: Yu X, et al.
Published: (2024-09-01)

Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
by: Zahirah Zaharuddin, et al.
Published: (2024-10-01)

Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review
by: Prabal Chourasia, et al.
Published: (2023-01-01)

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context
by: Shuxia Wang, et al.
Published: (2024-03-01)

Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab
by: Tal Brosh-Nissimov, et al.
Published: (2024-02-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Nirmatrelvir plus ritonavir in patients with underlying rheumatological diseases, in preventing COVID-19 related hospitalization and death
by: Faiza Javed, et al.
Published: (2024-07-01)

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
by: Jinhua Huang, et al.
Published: (2022-08-01)

Automated vs. manual case investigation and contact tracing for pandemic surveillance: Evidence from a stepped wedge cluster randomized trialResearch in context
by: Cameron Raymond, et al.
Published: (2023-01-01)

Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trialResearch in context
by: Gernot Rohde, et al.
Published: (2023-11-01)

Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19
by: Christopher G. Rowan, et al.
Published: (2024-12-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
by: Tatsuhiko Wada, et al.
Published: (2020-05-01)

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialResearch in context
by: Teresa H. Evering, et al.
Published: (2024-09-01)

Tacrolimus toxicity in a liver-kidney transplant patient receiving Nirmatrelvir/Ritonavir for COVID-19
by: Santiago F. Galeano Lovera, et al.
Published: (2023-12-01)

Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
by: Alexander M. Kaizer, et al.
Published: (2023-03-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Clinical rebound after treatment with nirmatrelvir/ritonavir in COVID-19
by: Daniel Camp, et al.
Published: (2024-09-01)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE – COALITION VIII randomised clinical trialResearch in context
by: Álvaro Avezum, et al.
Published: (2023-06-01)

Efficacy of lopinavir/ritonavir plus interferon beta compared to hydroxychloroquine in the treatment of COVID-19: A retrospective observational study
by: Motahareh Amirizadeh, et al.
Published: (2023-01-01)